ABSTRACT
Sickle cell trait (AS) and α-thalassemia trait are common conditions that affect the African American population at about 7.3% and 30%, respectively.
1,2 AS has been thought to be clinically benign but can lead to vascular occlusion under conditions of dehydration or decreased oxygenation and may increase the risk of chronic renal disease.
3,4 α-Thalassemia is associated with a spectrum of findings depending on the genotype. Deletions of one or two α globin genes may result in clinical silence to mild microcytic anemia, while deletions of three or four α globin genes result in hemoglobin (Hb) H disease and hydrops fetalis, respectively. 5 Diagnosis of either condition has important implications in family planning, helping to assess the risk and severity of sickle cell disease or α-thalassemia in offspring.
Hemoglobinopathy evaluation is used in the workup of both AS and α-thalassemia trait. When both entities are encountered in the same patient, the percentage of sickle Hb (HbS) can become a sensitive indicator of possible underlying α-thalassemia trait when used in conjunction with microcytic RBC indices. [6] [7] [8] In an analysis of 74 AS iron-replete patients on the Bio-Rad Variant II (BioRad, La Jolla, CA) high-performance liquid chromatography (HPLC) instrument, HbS% values of 29% to 35%, and less than 29% correlated with one and two α globin gene deletions, respectively. 9 The percentage of HbA 2 was found to increase with progressive loss of α globin genes in patients with AS, contrary to what is seen in patients with homozygous normal hemoglobin (AA). These findings are thought to be caused by the higher affinities between α chains and normal β and δ chains compared with sickle β chains, which result in a competitive disadvantage for the latter during thalassemic α chain restriction. HbA 2 % is less sensitive and specific for α globin gene deletions in patients with AS, underlining the importance of accurate HbS% measurement when considering the possibility of underlying α-thalassemia trait.
Diabetes mellitus (DM) is another common condition within the African American population, with a prevalence of about 21.8%. 10 While the diagnosis of type 2 diabetes is most often dependent on the quantity of HbA 1c , minor hemoglobins and hemoglobin variants are also subject to glycosylation. 11 Altered glycosylation could potentially affect Hb percent (Hb%) quantitation, especially with hemoglobin variants in which the elution/ migration characteristics of glycoforms are poorly understood. Specifically, the effect of DM on the evaluation of AS has not been described, to our knowledge. The current study presents a method comparison between the two most popular techniques of hemoglobinopathy evaluation, 12 HPLC and capillary electrophoresis (CE), for the evaluation of AS patient specimens across a range of HbA 1c %. In addition, a mechanism for discrepant Hb% measurements and a strategy for avoidance of interferences are described.
Materials and Methods
A prospective study was performed in accordance with a protocol (HUM00112224) approved by the Institutional Review Board of the University of Michigan Medical School, Ann Arbor. Specimens from 57 unique patients with AS and 38 unique patients with AA that were routinely submitted for clinical hemoglobinopathy evaluation or HbA 1c % quantitation were consecutively collected for the study. All specimens were received in lavender-top EDTA-containing tubes. For hemoglobinopathy evaluation, all specimens were analyzed by the Bio-Rad Variant II HPLC using the β-thalassemia short program (Bio-Rad) and the Sebia Capillarys 2 Flex Piercing CE (Sebia SA, Lisses, France) per manufacturer guidelines. By HPLC, percentages of HbA 2 , HbF, and HbS were obtained directly from the instrument, while the percentage of HbA was calculated as 100% -(HbA 2 % + HbF% + HbS%). By CE, all Hb% were obtained directly from the instrument. HbA 1c % was measured on the Tosoh G8 Glycohemoglobin analyzer (Tosoh Bioscience, San Francisco, CA) per manufacturer guidelines. HbA 1c % was calculated essentially using the ratio of the SA 1c fraction to the sum of the "A1a," "A1b," "LA1c," "SA1c," and "A0" fractions, excluding the "FP" peak, "HbF" peak, and any variant hemoglobin peaks eluting after "A0." 13 This ratio was then converted For each specimen, they were asked if their interpretations or diagnostic certainty for their interpretations changed depending on whether the Hb% results were obtained via HPLC or CE. Observers were also asked to comment on such diagnostic dilemmas by providing differential diagnoses based on each set of Hb%. Because clinical histories and recent iron status are pieces of information that often do not accompany the hemoglobinopathy evaluation specimens we see in our clinical practice, observers were not asked to distinguish between underlying thalassemia and iron deficiency. The results of the survey were analyzed for a correlation with the HbA 1c % of the specimens. Comments were reviewed for commonalities in interpretation changes based on the discrepant Hb%.
Data were analyzed as indicated using GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA). Method comparisons were analyzed using Bland-Altman difference plots. A two-tailed, nonpaired Mann-Whitney U test was used to evaluate for significance.
Results
Thirty-eight specimens from patients with AA and 57 specimens from patients with AS were collected for the study ❚Table 1❚. Diabetic patients, as defined by HbA 1c % of 6.5% or more, accounted for 24.2% of the study population, representing 34.2% of patients with AA and 17.5% of patients with AS. Two main differences are apparent in the patient groups. First, there were disproportionately more specimens from female patients with AS. Second, the median age of patients with AS was significantly lower than that of patients with AA. Importantly, diabetic patients with AA and AS were not significantly discrepant in age (P = .4736) and HbA 1c % (P = .7493) distributions. These observations are likely due to the fact that most AA specimens were collected from routine HbA 1c % testing, which was likely enriched for older patients and known patients with DM undergoing monitoring. In contrast, most AS specimens were collected from routine hemoglobinopathy evaluations, which were enriched with prenatal maternal workups and confirmations of abnormal newborn screens.
Specimens from patients with AS were analyzed by HPLC and CE ❚Figure 1❚. Forty-seven samples were from nondiabetic patients (open circles and bars) and showed intermethod concordance in HbS%, HbA%, HbA 2 %, and HbF% measurement, with median differences of 0.6%, 0.0%, -0.5%, and 0.0%, respectively ❚Table 2❚. The complementarily positive difference in HbS% measurement and negative difference in HbA 2 % measurement are consistent with a previously described HbS glycation product that coelutes with HbA 2 by HPLC but comigrates with the main HbS peak by CE.
14 Ten specimens from diabetic patients with AS ( Figure 1 , closed circles and bars) showed poor intermethod concordance in HbA% and HbS% measurement. Compared with CE, HPLC underquantified HbS% by a median difference of 4.9% (Table 2) and by a maximum difference up to 7.4% (Figure 1 ), representing a relative underquantitation of as much as approximately 25%. Complementing the underquantitation of HbS%, HPLC overquantified HbA% by a median difference of 3.8% ( Figure 1 and Table 2 ).
Specimens from patients with AA were similarly analyzed by HPLC and CE ❚Figure 2❚, including 25 from nondiabetic patients (open circles and bars) and 13 from diabetic patients (closed circles and bars). In contrast to AS specimens, all AA specimens showed excellent intermethod concordance in the measurement of HbA%, HbA 2 %, and HbF% (Table 2) , regardless of diabetic status. The largest intermethod differences were found in the measurement of HbA%, accounting for relative differences of less than 1.0% (Table 2) . Rarely, differences of up to 0.7% were detected when measuring HbF% in both diabetic and nondiabetic patients with AA; however, these differences were not clinically significant since the affected results stayed within previously determined reference ranges.
The intermethod differences in HbS% and HbA% in specimens from patients with AS were dependent on the HbA 1c % of each specimen ❚Figure 3❚. Furthermore, for each AS specimen with HbA 1c % of 6.5% or more ( Figure 3 , gray background), a positive measurement difference in HbS% was always accompanied by a negative measurement difference in HbA%. In contrast, no HbA 1c % dependence was noted for the small intermethod differences in AA specimens. Together, these data suggest that, with increasing HbA 1c % in specimens from patients with AS, a portion of HbS becomes increasingly misidentified as HbA by HPLC.
Inspection of the HPLC chromatograms and CE electropherograms revealed the source of the HbS% and HbA% intermethod measurement differences. Comparing specimens from a nondiabetic (HbA 1c % = 5.0%; ❚Figure 4A❚) and a severely diabetic (HbA 1c % = 13.2%; ❚Figure 4C❚) patient with AA showed a prominently increased P2 peak at 1.2 minutes by HPLC in the latter, which has been reported to represent stable HbA 1c . 15 Similarly, comparing specimens from a nondiabetic (HbA 1c % = 4.6%; ❚Figure 4E❚) and a severely diabetic (HbA 1c % = 15.4%; ❚Figure 4G❚) patient with AS showed a prominent P2 peak in the latter. However, an unknown peak eluting at 2.3 minutes (P2.3) just prior to the HbA 0 peak was also found to be more prominent in the diabetic AS patient sample ( Figure 4G ), raising the possibility that this unknown peak was the HbS version of HbA 1c , or HbS 1c . Even though a small peak at 2.3 minutes could be identified by visual inspection in all AS specimens, the Bio-Rad Variant II software did not automatically identify and quantify P2.3 until the specimen HbA 1c % was 9.9% or more ( Supplementary Figure 1; all supplemental materials can be found at American Journal of Clinical Pathology online). Importantly, no P2.3 peaks were identified in any AA specimen either by the software or by visual inspection of the electropherograms.
In contrast, by CE, little difference was observed between the two AA patient samples or between the two AS patient samples. In the severely diabetic AA sample ❚Figure 4D❚ but not the nondiabetic AA sample ❚Figure 4B❚, a tiny extra peak migrated in the Z10 zone. This Z10 peak has been identified by the instrument manufacturer as a small amount of HbA 1c that appears when HbA 1c % is more than 10%, with the predominant portion of HbA 1c comigrating with HbA. 16 The tiny Z10 zone peak next to HbA and an additional tiny Z(D) zone peak next to HbS were seen in the severely diabetic AS patient sample ❚Figure 4H❚ but in not the nondiabetic AS sample In patients with AA, labile HbA 1c elutes in HPLC immediately prior to the P2 peak of stable A1c, 17 making stable HbA 1c easily identifiable. Indeed, incubation of a diabetic AA patient specimen with excess glucose induces a prominent peak at 1.1 minutes adjacent to P2 ❚Figure 5A❚ and ❚Figure 5B❚, consistent with a doublet of labile and stable HbA 1c peaks. We therefore tested the hypothesis that P2.3 in HbS-containing specimens was HbS 1c by similarly incubating a specimen from a homozygous HbS (SS) sickle cell disease patient with excess glucose to identify the labile HbS 1c peak. A nontransfused SS patient specimen was selected to prevent interference from a HbA 0 peak. Incubation with glucose induced a prominent labile HbS 1c peak at 2.1 minutes, indicating that the adjacent P2.3 was stable HbS 1c ❚Figure 5C❚ and ❚Figure 5D❚. Thus, in a diabetic patient with AS, hemoglobinopathy evaluation by HPLC can reveal a prominent stable HbA 1c peak at P2 as well as a notable stable HbS 1c at P2.3, which can be erroneously integrated as part of the HbA 0 peak at 2.5 minutes and lead to underquantitation of HbS%.
To determine whether the intermethod differences in Hb% measurement in AS patient specimens affected diagnostic interpretation, five expert observers were asked to evaluate each of the 57 AS patient cases in this study. They were supplied with patient age and sex, Hb% values from HPLC and CE, and RBC indices but were blinded to HbA 1c %. They were asked to respond as to whether their diagnostic interpretations changed depending on how Hb% were measured and, if so, how such interpretations were changed. This survey found that the method of Hb% (Table 3 , case 1). While both HPLC and CE reported HbS% to be slightly low at 33.6% and 34.8%, respectively, observers were less willing to consider underlying α-thalassemia trait and/or iron deficiency based on CE values. Because severe DM affects the certainty with which observers can diagnose underlying α-thalassemia and/ or iron deficiency in patients with AS by HPLC, it is important to determine which cases are best evaluated by CE. Since HbA 1c is an appropriate biomarker for the diagnosis of DM in patients with AS, and since HbA 1c elutes as a well-defined peak in P2 by HPLC, we tested whether P2% could be used to identify patients with AS with severe DM. ❚Figure 6❚ shows a linear relationship between P2% and HbA 1c % in AA as well as AS specimens. The slope of the linear regression fit for AS specimens (0.74 ± 0.01, r 2 = 0.9875) was smaller than that for AA specimens (1.06 ± 0.01, r 2 = 0.9973). This is consistent with the 1c glycohemoglobin fraction eluting completely as peak P2 in AA specimens while being divided between peaks P2 and P2.3 in AS specimens. As a screen to identify severely diabetic patients with AS, P2% of more than 4.1% detected patients with A 1c % of 8.0% or more with 100% sensitivity (95% confidence interval [CI], 66.4%-100%) and 100% specificity (95% CI, 92.6%-100%) in our limited data set (Supplementary Table 1 ).
Discussion
Due to the close elution times between HbS 1c and HbA 0 , misquantification of HbS% is a potential analytical error when performing hemoglobinopathy evaluation by HPLC on the Bio-Rad Variant II. From experiments with SS patient specimens, HbS 1c was found to elute at 2.3 minutes, overlapping with the elution front of HbA 0 , whose elution peak is at 2.5 minutes. AS patient specimens always contain baseline amounts of HbA 1c and HbS 1c , which can be seen by HPLC as the P2 and P2.3 peaks, respectively. DM increases both HbA 1c and HbS 1c and, therefore, also increases P2 and P2.3 by HPLC. Consequently, worsening diabetic status is associated with increasingly mismeasured HbS% as more and more HbS 1c is coquantified with HbA. However, the Variant II software does not automatically identify and quantify P2.3 until HbA 1c % is 9.9% or more, precluding arithmetic correction. This is not an issue in CE on the Sebia Capillarys 2 Flex Piercing, in which HbA 1c and HbS 1c predominantly comigrate with HbA and HbS, respectively. Small HbA 1c and HbS 1c peaks can be distinctly seen in CE but are rarely integrated by the HEMOGLOBIN(E) software (Sebia) . When actually integrated, each glycohemoglobin peak accounts for less than 1% of the total peak area, even in our most severely diabetic patient specimen. Thus, we believe that in diabetic patients with AS, CE measures Hb% more accurately than HPLC.
In our data set, expert observers reported that intermethod discrepancies in HbS% affected their ability to evaluate for underlying α-thalassemia trait or iron deficiency in some diabetic AS cases but not until HbA 1c % was 9.9% or more. This leads to several options on how clinical laboratorians who use HPLC, especially the BioRad Variant II, as a primary method may choose to manage hemoglobinopathy evaluation in diabetic patients with AS. These options depend on what alternate techniques a laboratory may have at hand for the confirmation of variant hemoglobins, as mandated by the College of American Pathologists. 18 If a laboratory uses CE as the secondary method for confirmation of HbS, laboratorians can then compare HPLC-and CE-derived Hb% to render their diagnostic interpretations. If a laboratory uses alternate techniques such as gel electrophoresis or HbS solubility tests to confirm the presence of HbS, laboratorians may wish to develop a strategy to determine which specimens should be analyzed by CE, perhaps at a reference laboratory if on-site CE is unavailable. Selection of potentially challenging samples can be based on the size of the HPLC P2 peak, wherein P2% of more than 4.1% identifies AS specimens with HbA 1c % of more than 8.0% and which therefore should be analyzed by CE. Some laboratorians ❚Figure 3❚ Dependence of intermethod hemoglobin measurement differences on hemoglobin A 1c (HbA 1c ) percent in homozygous normal hemoglobin (AA) and sickle cell trait (AS) patient specimens. Data symbols in the gray area represent specimens with HbA 1c % of 6.5% or more.
may wish to direct the Bio-Rad Variant II software to quantify P2.3 in all AS specimens and simply add that amount to the S-window peak. This is an approach that was not in our original study design and thus will have to be validated in a prospective manner.
HbS% cutoff values of 29% to 35% and less than 29% that identify patients with AS with underlying one α globin gene deletion and two α globin gene deletions, respectively, were developed using HPLC on the Bio-Rad Variant II platform. 9 To our knowledge, HbS% cutoffs have not been similarly defined for CE using AS cases with known α globin genotypes. However, in nondiabetic AS cases, we found that HPLC underquantified HbS% only by a median difference of 0.6% compared with CE. Therefore, the HPLC-based HbS% cutoff values should be applicable to most AS cases analyzed by CE. Cases with borderline CE-derived HbS%, such as just above or below 35%, could be managed with appropriate differential diagnoses in commentary.
Limitations of the study are related to the fact that many of the specimens were referred from outside providers. Only EDTA-anticoagulated specimens were available, precluding the performance of iron studies. In addition, very little clinical history was available, including molecular studies for thalassemia and recent iron status. Therefore, this study only focused on the performance of two techniques to accurately quantify Hb% and the impact of those results on diagnostic interpretation, reflecting our real-world hemoglobinopathy evaluation sign-out experience. Furthermore, although the instruments studied are currently the most widely used systems for each technique in the United States, 12 only one manufacturer's HPLC instrument and one manufacturer's CE instrument were evaluated in this study. The findings may not be transferable to other HPLC or CE instruments; however, confirmation of the interference described here on other analytic platforms should be straightforward.
In conclusion, the Bio-Rad Variant II HPLC hemoglobin analyzer is subject to mismeasurement of Hb% in patients with AS who are severely diabetic, owing to coelution of HbS 1c with HbA 0 . Inaccurate Hb%, especially HbS%, can lead to misinterpretations of the likelihood of underlying α-thalassemia trait or iron deficiency. Because glycosylated and unmodified hemoglobins predominantly comigrate in CE, Hb% measurement in patients with AS by the Sebia Capillarys 2 Flex Piercing hemoglobin analyzer was insensitive to severe DM. The recognition of this interference by the Bio-Rad Variant II will improve the diagnostic accuracy of concurrent α chain restricting conditions in patients with AS. 
